arrow
A

Anupriya Aggarwal

nsw health
H指数:27
被引数:2,325

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Polyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID-19
2025-12-180
OAAI
P selectin promotes SARS-CoV-2 interactions with platelets and the endothelium

P selectin促进SARS-CoV-2与血小板和内皮细胞的相互作用

2025-11-170
PRE
Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants

二价Omicron BA.1疫苗加强剂增加记忆b细胞宽度并中和针对新兴SARS-CoV-2变体的抗体

2024-12-010
OAAI
Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the fi rst four years of the COVID-19 pandemic
2024-12-010
OAAI
Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS-CoV-2 Main Protease with Antiviral Activity

利用疏水性氨基酸扫描开发具有抗病毒活性的SARS-CoV-2主蛋白酶环肽抑制剂

2024-07-170
OA
Dietary Inulin to Improve SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients: The RIVASTIM-Inulin Randomised Controlled Trial

膳食菊粉可改善肾移植受者的SARS-CoV-2疫苗反应: RIVASTIM-菊粉随机对照试验

2024-06-031
OAAI
Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

SARS-CoV-2感染后24个月长COVID个体免疫失调的改善

2024-04-176
OAAI
Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity

具有SARS-CoV-2进入抑制活性的人ACE2高亲和力环肽配体的发现

2023-12-124
PRE
Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection

Omicron突破性感染后中和抗体反应的持久重编程

2023-07-2111
OAAI
Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naive Children and Adults

感染和疫苗诱导的针对COVID-19-Naive儿童和成人的SARS-CoV-2变异的尖峰抗体反应

2023-07-050
OAAI
A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein

SARS-CoV-2刺突蛋白的广谱大环肽抑制剂

2023-06-2011
OAAI
Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

骨髓纤维化患者接种疫苗后对SARS-CoV-2祖先和Omicron BA.5变体的体液和细胞免疫

2023-04-102
OAAI
Emergence and antibody evasion of BQ, BA.2.75 and SARS- CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level

面对人群水平上成熟的抗体广度,BQ,BA.2.75和传染性非典型肺炎CoV-2的重组亚谱系的出现和抗体逃逸

2023-04-0121
OAAI
High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells

响应SARS-CoV-2感染的高滴度中和抗体需要RBD特异性CD4 T细胞,包括增殖记忆细胞

2022-12-0511
OAAI
A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae

持续的中性粒细胞相关免疫特征是post-COVID-19肺后遗症的特征

2022-11-1649
OA
Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

基于粘膜TLR2-activating蛋白的疫苗接种可诱导小鼠有效的肺部免疫和SARS-CoV-2保护

2022-11-1521
OAAI
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

SARS-CoV-2 Omicron BA.5: 进化趋向性和逃避有效的体液反应和抵抗临床免疫治疗相对于病毒变异的关注

2022-10-0162
OAAI
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses

用BNT162b2免疫治疗的惰性淋巴瘤患者的抗刺中和IgG SARS-CoV-2变体减少,但保留了抗原特异性T细胞反应

2022-06-0912
OAAI
SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
2022-06-0127
OAAI